SCHEMBL5715599

SCHEMBL5715599

CC1(C)CC(=O)N(CCc2ccc(OC(=O)N3CCN(c4ccccn4)CC3)nc2)C(=O)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
HSD17B10 Q99714 8/20 0.43
HPGD P15428 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 3/20 0.43
TSHR P16473 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2D6 P10635 1/20 0.42
LMNA P02545 1/20 0.41
HTR7 P34969 2/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714651 0.90 HSD17B10 (0.52) ALDH1A1HSD17B10HPGDL3MBTL1NPSR1
SCHEMBL5715321 0.88 HTR1A (0.39) SMN1; SMN2HTR1ADRD2HTR2AHTR2C
SCHEMBL5715059 0.88 AOC3 (0.40) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL5714605 0.87 AOC3 (0.42) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL5714637 0.87 ALDH1A1 (0.48) ALDH1A1NPSR1KDM4ETSHRMAPK1
SCHEMBL5715118 0.87 ME2 (0.43) HPGDSMN1; SMN2HTR7HTR1ADRD2
SCHEMBL5714563 0.87 ME2 (0.43) HTR7HTR1ADRD2HTR2AHTR2C
SCHEMBL5714515 0.86 TP53 (0.43) ALDH1A1KDM4ELMNAHTR1ADRD2
SCHEMBL5715436 0.86 HRH3 (0.41) ALDH1A1HPGDSMN1; SMN2TSHRLMNA
SCHEMBL5714782 0.85 SMN1; SMN2 (0.53) ALDH1A1HPGDL3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ALDH1A1 1021/4885HSD17B10 285/4885HPGD 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.